Detalhe da pesquisa
1.
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180219
2.
Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
Mult Scler
; 28(12): 1937-1943, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35723265
3.
Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study.
Value Health
; 25(9): 1489-1498, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484029
4.
Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report.
Int J Mol Sci
; 23(21)2022 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36362428
5.
The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity.
Ann Neurol
; 88(3): 562-573, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32418239
6.
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mult Scler
; 27(5): 790-794, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749910
7.
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
Mult Scler
; 27(3): 331-346, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940121
8.
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
Mult Scler
; 27(3): 347-359, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940128
9.
Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
Eur J Neurol
; 28(8): 2533-2542, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786942
10.
Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Neurol Sci
; 42(7): 2837-2845, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33205373
11.
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-ß therapy of multiple sclerosis patients.
J Transl Med
; 18(1): 169, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299447
12.
Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
J Neurovirol
; 26(1): 133-137, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468472
13.
Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
Mult Scler
; 26(10): 1227-1236, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31144589
14.
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
Ann Neurol
; 83(4): 739-755, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29518260
15.
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
J Neurol Neurosurg Psychiatry
; 90(3): 261-267, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30389778
16.
Impact of natural menopause on multiple sclerosis: a multicentre study.
J Neurol Neurosurg Psychiatry
; 90(11): 1201-1206, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189614
17.
Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
Mult Scler
; 25(8): 1196-1201, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30964396
18.
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
Neurol Sci
; 40(10): 2119-2124, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175467
19.
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.
Ann Neurol
; 82(5): 697-705, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023856
20.
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.
J Neurovirol
; 23(5): 742-749, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28791614